Results 41 to 50 of about 1,222 (132)

Comprehensive update on the monkeypox outbreak

Frontiers in Microbiology, 2022
Monkeypox (MPX) was first reported in 1970 in humans and outbreaks were restricted and highly localised to endemic regions of western and central Africa.
Asad Mustafa Karim, Jeong Eun Kwon, Mujahid Aizaz Karim, Haseeb Iftikhar, Muhammad Yasir, Muhammad Yasir, Irfan Ullah, Se Chan Kang   +7 more
doaj   +1 more source

Candidate Vaccines and Therapeutics against Monkeypox Infection

Journal of Pure and Applied Microbiology, 2022
While human beings are still facing the challenges of the pandemic coronavirus disease (COVID-19), a new viral disease, monkeypox raises concerns among healthcare authorities about this new threat.
Nidhi Nainwal, Vikash Jakhmola
doaj   +1 more source

Genomic Characterization of the Historical Smallpox Vaccine Strain Wyeth Isolated from a 1971 Seed Vial

Viruses, 2022
The Wyeth strain of vaccinia virus (VACV) produced by Wyeth Pharmaceuticals was supposedly used to manufacture the old freeze-dried American smallpox vaccine, Dryvax, until its discontinuation in 2008.
Nádia Vaez G. Cruz, Matheus Nobrega Luques, Terezinha Marta Pereira P. Castiñeiras, Orlando Costa Ferreira Jr, Regina Helena S. Peralta, Luciana J. da Costa, Clarissa R. Damaso   +6 more
doaj   +1 more source

ACAM2000 vaccine safety and immunogenicity considerations for smallpox and mpox

Expert Review of Vaccines
Introduction Smallpox, eradicated globally in 1980, remains a major biodefense concern due to retained Variola virus stocks and the absence of population immunity following cessation of routine vaccination. Monkeypox virus (MPXV), a related orthopoxvirus,
Vanja Komlenovic, James McCarty, David Cassie, Ravi Anantha, Kevin Yeo, Mario Rodriguez, Bojan Drobic   +6 more
doaj   +1 more source

Discovery and Structural Characterization of a Highly Protective Neutralizing Antibody Targeting the Mpox Virus A35R Protein

MedComm, Volume 7, Issue 7, July 2026.
High‐affinity monoclonal antibodies (mAbs) targeting the MPXV EEV protein A35R were rapidly isolated using mRNA‐LNP vaccination and the Beacon single‐cell sorting Optofluidic platform, followed by functional profiling. One mAb, 17H1, potently neutralized authentic MPXV and conferred complete protection in vivo.
Shimeng Bai, Shuo Song, Xin Wang, Yuxin Xiao, Yun Long, Fenfang Wu, Fuxiang Wang, Zhongyi Fan, Jianqing Xu, Maozhou He, Hongzhou Lu   +10 more
wiley   +1 more source

Monkeypox vaccine – Current status

Journal of Integrative Medicine and Research, 2023
From a long time ago, there have been intermittent outbreaks of the zoonotic disease monkeypox (mpox) throughout Africa. The first case of human mpox was documented in 1970 in rural Congo. Mpox was classified as a Public Health Emergency of International
Brig Ambika Mohanty, Aroop Mohanty
doaj   +1 more source

Monkeypox virus infection – Evolution, molecular biology, epidemiology, clinical features and management aspects

Current Medicine Research and Practice, 2022
Monkeypox virus (MPXV) infection has lately emerged as a new public health problem across 100 countries. Surging cases of MPXV infection in non-endemic countries prompted the World Health Organization to declare it a public health emergency in July 2022.
Dinesh Kaul, Kavita Yadav, Akanksha Bansal   +2 more
doaj   +1 more source

Sex Differences in Response to Viral Vector Vaccines—Implications for Future Vaccine Design

Immunological Reviews, Volume 338, Issue 1, March 2026.
ABSTRACT Vaccination represents one of the most impactful public health achievements, preventing 3.5 to 5 million deaths annually according to estimates of the World Health Organization. Yet, recent outbreaks of emerging and reemerging infectious diseases highlight the need for rapid and strategic vaccine development using vaccine platforms ...
Ilka Grewe, Tamara Zoran, Marylyn Martina Addo   +2 more
wiley   +1 more source

An mRNA Vaccine Based on Antigens From Conserved Regions of Monkeypox Virus A35R and M1R With a Dimer‐Like Conformation Confers Protection Against Both Monkeypox Virus and Vaccinia Virus Infections in Mice

MedComm, Volume 7, Issue 2, February 2026.
We developed four candidate mRNA vaccine antigens based on conserved sequences of MPXV A35R and M1R proteins. Our findings demonstrate that the MV2 vaccine possesses favorable immunogenicity and prophylactic potential against MPXV and VACV infections, positioning it as a promising clinical candidate for MPXV prevention.
Cong Tang, Longhai Yuan, Yun Xie, Yun Yang, Yanan Zhou, Junbing Wang, Hao Yang, Rui Peng, Jiali Xu, Wenhai Yu, Qing Huang, Wenqi Quan, Baisheng Li, Youchun Wang, Shuaiyao Lu   +14 more
wiley   +1 more source

Organoid Models to Study Human Infectious Diseases

Cell Proliferation, Volume 58, Issue 11, November 2025.
Our manuscript reviews the role of organoids as models for studying human infectious diseases, highlighting their irreplaceable contributions to drug testing and vaccine development for significant infectious diseases including HIV, ZIKV, SARS‐CoV‐2 and MPXV.
Sijing Zhu, Dan Chen, Xinzhi Yang, Liuliu Yang, Yuling Han   +4 more
wiley   +1 more source